PH12022550078A1 - Enzyme inhibitors - Google Patents
Enzyme inhibitorsInfo
- Publication number
- PH12022550078A1 PH12022550078A1 PH1/2022/550078A PH12022550078A PH12022550078A1 PH 12022550078 A1 PH12022550078 A1 PH 12022550078A1 PH 12022550078 A PH12022550078 A PH 12022550078A PH 12022550078 A1 PH12022550078 A1 PH 12022550078A1
- Authority
- PH
- Philippines
- Prior art keywords
- enzyme inhibitors
- compounds
- therapy
- compositions
- formula
- Prior art date
Links
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2019/052359 WO2021032936A1 (en) | 2019-08-21 | 2019-08-21 | Enzyme inhibitors |
| PCT/GB2020/050332 WO2021032937A1 (en) | 2019-08-21 | 2020-02-13 | Enzyme inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022550078A1 true PH12022550078A1 (en) | 2022-11-21 |
Family
ID=67777359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/550078A PH12022550078A1 (en) | 2019-08-21 | 2020-02-13 | Enzyme inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220363668A1 (https=) |
| EP (1) | EP4017587A1 (https=) |
| JP (1) | JP7566870B2 (https=) |
| KR (1) | KR20220051207A (https=) |
| CN (1) | CN114269430A (https=) |
| AR (1) | AR118085A1 (https=) |
| AU (1) | AU2020333222A1 (https=) |
| BR (1) | BR112022000936A2 (https=) |
| CA (1) | CA3147228A1 (https=) |
| CO (1) | CO2022000266A2 (https=) |
| IL (1) | IL289783A (https=) |
| MX (1) | MX2022002069A (https=) |
| PH (1) | PH12022550078A1 (https=) |
| TW (1) | TW202115033A (https=) |
| WO (2) | WO2021032936A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032935A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| WO2025153806A1 (en) * | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| CN103415301A (zh) * | 2011-03-09 | 2013-11-27 | 德国杰特贝林生物制品有限公司 | 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂 |
| GB2517908A (en) * | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| WO2015171527A1 (en) * | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| WO2017123518A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
| AU2017269256B2 (en) | 2016-05-23 | 2021-02-25 | The Rockefeller University | Aminoacylindazole immunomodulators for treatment of autoimmune diseases |
| WO2018093695A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
| EP3541381B1 (en) | 2016-11-18 | 2022-12-28 | Merck Sharp & Dohme LLC | Inhibitors of factor xiia |
| JP2021504490A (ja) | 2017-11-29 | 2021-02-15 | ザ ロックフェラー ユニバーシティーＴｈｅ Ｒｏｃｋｅｆｅｌｌｅｒ Ｕｎｉｖｅｒｓｉｔｙ | 自己免疫疾患治療用ピラノピラゾールおよびピラゾロピリジン免疫調節薬 |
| WO2021032935A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
-
2019
- 2019-08-21 EP EP19759703.2A patent/EP4017587A1/en not_active Withdrawn
- 2019-08-21 CN CN201980099528.XA patent/CN114269430A/zh active Pending
- 2019-08-21 WO PCT/GB2019/052359 patent/WO2021032936A1/en not_active Ceased
-
2020
- 2020-02-13 CA CA3147228A patent/CA3147228A1/en active Pending
- 2020-02-13 BR BR112022000936A patent/BR112022000936A2/pt not_active Application Discontinuation
- 2020-02-13 AU AU2020333222A patent/AU2020333222A1/en active Pending
- 2020-02-13 JP JP2022503825A patent/JP7566870B2/ja active Active
- 2020-02-13 MX MX2022002069A patent/MX2022002069A/es unknown
- 2020-02-13 AR ARP200100399A patent/AR118085A1/es not_active Application Discontinuation
- 2020-02-13 US US17/634,367 patent/US20220363668A1/en not_active Abandoned
- 2020-02-13 PH PH1/2022/550078A patent/PH12022550078A1/en unknown
- 2020-02-13 KR KR1020227008821A patent/KR20220051207A/ko not_active Withdrawn
- 2020-02-13 TW TW109104437A patent/TW202115033A/zh unknown
- 2020-02-13 WO PCT/GB2020/050332 patent/WO2021032937A1/en not_active Ceased
-
2022
- 2022-01-12 IL IL289783A patent/IL289783A/en unknown
- 2022-01-17 CO CONC2022/0000266A patent/CO2022000266A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4017587A1 (en) | 2022-06-29 |
| AR118085A1 (es) | 2021-09-15 |
| MX2022002069A (es) | 2022-03-17 |
| IL289783A (en) | 2022-03-01 |
| CO2022000266A2 (es) | 2022-01-28 |
| CA3147228A1 (en) | 2021-02-25 |
| KR20220051207A (ko) | 2022-04-26 |
| US20220363668A1 (en) | 2022-11-17 |
| TW202115033A (zh) | 2021-04-16 |
| AU2020333222A1 (en) | 2022-02-24 |
| JP2022545158A (ja) | 2022-10-26 |
| WO2021032936A1 (en) | 2021-02-25 |
| CN114269430A (zh) | 2022-04-01 |
| WO2021032937A1 (en) | 2021-02-25 |
| JP7566870B2 (ja) | 2024-10-15 |
| BR112022000936A2 (pt) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552497A1 (en) | Enzyme inhibitors | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| NZ784224A (en) | Parp1 inhibitors | |
| ZA201907052B (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| PH12022550124A1 (en) | Enzyme inhibitors | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| PH12022550029A1 (en) | Deuterated mk2 pathway inhibitors and methods of using the same | |
| NZ709609A (en) | Benzylamine derivatives | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| MX2021001565A (es) | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
| ZA202006612B (en) | Antibacterial compounds | |
| ZA201800787B (en) | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy | |
| MX2022000545A (es) | Inhibidores de enzimas. | |
| PH12022552489A1 (en) | V delta1+ t cells for the treatment of myeloid malignancies | |
| MX2023009677A (es) | Inhibidores de enzimas. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof |